# NUV-1511

Source: https://onco.cc/drugs/nuv-1511/  
OnCo record `nuv-1511` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NUV-1511 is a small-molecule inhibitor from Nuvation Bio Inc., in registered phase 2 trials for prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer.

## Summary

NUV-1511 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Nuvation Bio Inc., in prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer. Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: NUV-1511
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of NUV-1511: https://clinicaltrials.gov/search?intr=NUV-1511

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Nuvation Bio](https://onco.cc/companies/nuvation-bio/)
- trials: [Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06334432/)

---
JSON: https://onco.cc/api/v1/entities/nuv-1511.json